التفاصيل البيبلوغرافية
| العنوان: |
Impact of apremilast on quality of life in Behçet’s syndrome: analysis of the phase 3 RELIEF study |
| المؤلفون: |
Hatemi, Gülen, Mahr, Alfred, Takeno, Mitsuhiro, Kim, Doyoung, Melikoğlu, Melike, Cheng, Sue, McCue, Shannon, Paris, Maria, Chen, Mindy, Yazici, Yusuf |
| المساهمون: |
Celgene |
| المصدر: |
RMD Open ; volume 8, issue 2, page e002235 ; ISSN 2056-5933 |
| بيانات النشر: |
BMJ |
| سنة النشر: |
2022 |
| مصطلحات موضوعية: |
Immunology, Immunology and Allergy, Rheumatology |
| الوصف: |
Objective To assess apremilast’s impact on patient quality of life (QoL) in active Behçet’s syndrome and correlations between improvement in patients’ QoL and efficacy measures in the phase 3 RELIEF study. Methods QoL measures included Behçet’s Disease QoL (BDQoL), 36-Item Short-Form Health Survey V.2 (SF-36v2) Physical/Mental Component Summary (PCS/MCS) and eight subscale scores, focusing on Physical Functioning (PF). Pearson’s correlation coefficients assessed relationships between efficacy endpoints (oral ulcer count, oral ulcer pain, Behçet’s Syndrome Activity Scale (BSAS), Behçet’s Disease Current Activity Form (BDCAF)) and QoL endpoints for apremilast at Week 12. Results Apremilast (n=104) demonstrated significantly greater improvements versus placebo (n=103) in SF-36v2 PCS (3.1 vs 0.9), MCS (4.6 vs ─0.7) and PF (2.9 vs 0.14), respectively (all p<0.05). Mild correlations were observed in improvements of SF-36v2 measures (PCS, MCS, PF) with oral ulcer count (r=−0.11, PCS), and change in oral ulcer pain from baseline (r=−0.28, PCS; r=−0.10, PF) and BSAS (r=−0.38, PCS; r=−0.20, PF; r=−0.16, MCS). Correlations among BDCAF and SF-36v2 components and BDQoL were variable. BDQoL showed mild/moderate correlations with SF-36v2 components (r=−0.18, PCS; r=−0.13, PF; r=−0.45, MCS). Conclusions Apremilast was associated with significant improvements in QoL measures of SF-36v2 PCS, MCS and PF and BDQoL in patients with Behçet’s syndrome. Correlations of improvement among QoL endpoints support the beneficial clinical effects of apremilast in Behçet’s syndrome. Trial registration number NCT02307513 . |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1136/rmdopen-2022-002235 |
| الإتاحة: |
https://doi.org/10.1136/rmdopen-2022-002235Test |
| حقوق: |
http://creativecommons.org/licenses/by-nc/4.0Test/ |
| رقم الانضمام: |
edsbas.F335586 |
| قاعدة البيانات: |
BASE |
